Filter Results
:
(297)
Show Results For
-
All HBS Web
(297)
- People (1)
- News (81)
- Research (185)
- Multimedia (3)
- Faculty Publications (123)
Show Results For
-
All HBS Web
(297)
- People (1)
- News (81)
- Research (185)
- Multimedia (3)
- Faculty Publications (123)
- 07 Apr 2003
- Research & Ideas
Three Steps for Crisis Prevention
genetically modified foods in Europe. Betting the company on a "life sciences" vision, Shapiro had sold or spun off Monsanto's traditional chemical businesses and moved aggressively to acquire seed companies. Dazzled by the...
View Details
Keywords:
by Michael D. Watkins & Max H. Bazerman
- Profile
Paris Wallace
Eric Boutin in 2008 in his last year at HBS. Good Start Genetics is now a successful late stage venture with more than 150 employees. The company offers a fertility diagnostic that allows parents to determine if their children are at risk...
View Details
- June 1997 (Revised September 1997)
- Case
Genset Initial Public Offering (B)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Supplements the (A) case.
View Details
Keywords:
Business Model;
Initial Public Offering;
Genetics;
Going Public;
Management Teams;
Biotechnology Industry;
France;
United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (B)." Harvard Business School Case 297-097, June 1997. (Revised September 1997.)
- June 1997 (Revised March 2001)
- Case
Genset Initial Public Offering (A)
By: Paul A. Gompers and Jeffrey M. Anapolsky
Pascal Brandys, founder and CEO of Genset, must decide whether to take this young biotechnology company public. If so, should he do a dual offering in both France and the U.S.? The case also explores the business models in genomics research.
View Details
Keywords:
Business Model;
Initial Public Offering;
Genetics;
Going Public;
Management Teams;
Biotechnology Industry;
France;
United States
Gompers, Paul A., and Jeffrey M. Anapolsky. "Genset Initial Public Offering (A)." Harvard Business School Case 297-096, June 1997. (Revised March 2001.)
- 17 Nov 2003
- Research & Ideas
The Business of Babies
fertilization (IVF), surrogacy, and adoption demand payments of $10,000 and up. The largest demand in this market consists of infertile couples. Last year, some two million U.S. couples underwent fertility treatments. Additional demand includes same-sex couples, those...
View Details
- 12 Nov 2015
- Research & Ideas
Can Consumers be Trusted with Their Own Health Care?
reveals a person’s genetically based health risk across dozens of disease categories. 23andMe test results showed one patient at higher risk of liver and bowel cancer—and that made sense, given family history. The patient discussed the...
View Details
- October 2010 (Revised November 2010)
- Background Note
Plavix: Drugs in the Age of Personalized Medicine
By: Richard G. Hamermesh, Mara G. Aspinall and Rachel Gordon
PIavix, one of the world's best selling drugs in 2010, appears to have a limited future. Its patent was due to expire soon, and recently new data had been discovered that indicated that a small subset of the population would be at risk for stroke, heart attack, or even...
View Details
Keywords:
Health Care and Treatment;
Product Positioning;
Business and Government Relations;
Genetics;
Competitive Strategy;
Pharmaceutical Industry
Hamermesh, Richard G., Mara G. Aspinall, and Rachel Gordon. "Plavix: Drugs in the Age of Personalized Medicine." Harvard Business School Background Note 811-001, October 2010. (Revised November 2010.)
- 05 Dec 2013
- Op-Ed
Encourage Breakthrough Health Care by Competing on Products Rather Than Patents
Like many people interested in the tangled connections between health care progress and intellectual property rights, I avidly followed the Myriad Genetics case, decided by the Supreme Court this June 13. In sum, molecular diagnostics...
View Details
- 01 Oct 2001
- News
Philip L. Yeo: The Next Big Thing
sciences and bioengineering. "In the next generation, we will know the genetic and molecular mechanisms of disease," Yeo declares. "Biomedical science will control and eradicate cancer and AIDS, and individualized medicine will be the...
View Details
Keywords:
Government
- 04 Nov 2021
- Blog Post
STUDENT SPOTLIGHT: JESSE LOU (MBA 2022) – WORKING TO CHANGE THE FOOD SYSTEM
oils, using a lot less land and resources. It’s no secret that these are powerful organisms, but past attempts to scale production have faced challenging unit economics (high up-front capital costs for facilities, selling into commodity markets). We believe that...
View Details
- 04 Nov 2021
- Blog Post
STUDENT SPOTLIGHT: JESSE LOU (MBA 2022) – WORKING TO CHANGE THE FOOD SYSTEM
oils, using a lot less land and resources. It’s no secret that these are powerful organisms, but past attempts to scale production have faced challenging unit economics (high up-front capital costs for facilities, selling into commodity markets). We believe that...
View Details
- 01 Jun 2000
- News
Managing the Map
Health (NIH) undertook the Human Genome Project, an effort to map the extraordinarily intricate chemical composition of the human genome. Scientists have long believed that understanding the vast genetic code underlying all human life...
View Details
Keywords:
Peter K. Jacobs
- January 2009 (Revised July 2010)
- Case
iZumi
By: Robert F. Higgins, Jacob Ian Broder-Fingert, Eliot Sherman and Sidhartha Palani
Presents the issues faced while building an innovative company in an emerging space with new intellectual property from the perspective of a venture capitalist. Beth Seidenberg, a partner at the venture capital firm Kleiner Perkins Caufield & Byers (KPCB), had helped...
View Details
- 14 Jul 2009
- First Look
First Look: July 14
Course MaterialsThe DiagnoFirst Opportunity Harvard Business School Case 309-112 John Mason, a principle at Oldwell Partners, was facing a decision of whether or not to invest in DiagnoFirst, a molecular diagnostics firm. DiagnoFirst's key product was a View Details
Keywords:
Martha Lagace
- 03 Mar 2015
- First Look
First Look: March 3
a lower price but charge more for the cartridges necessary to run a sample and earn its primary revenue from these cartridges. The third model would see GenapSys sell its device at or around cost, but use the data customers generated to create a proprietary database of...
View Details
Keywords:
Sean Silverthorne
- October 2001 (Revised March 2008)
- Case
Anagene, Inc.
By: Robert S. Kaplan and Christina L. Darwall
An entrepreneurial, publicly traded biotech company has begun production and sales of its core product--cartridges that permit DNA samples to be analyzed on a microchip. In the early quarters, sales are difficult to forecast and the company has experienced fluctuating...
View Details
Keywords:
Cost Accounting;
Financial Reporting;
Production;
Performance Capacity;
Risk and Uncertainty;
Genetics;
Governing and Advisory Boards;
Biotechnology Industry;
California
Kaplan, Robert S., and Christina L. Darwall. "Anagene, Inc." Harvard Business School Case 102-030, October 2001. (Revised March 2008.)
- Web
New Venture Competition 2024: Business and Environment Ventures - Blog - Business & Environment
genetic insights. Watch Crop Diagnostix at the 2024 New Venture Competition. 2024 Social Enterprise Track Winner: Solara - Rea Savla (MBA 2024), Vishesh Mehta - Providing an on-demand solar irrigation service to Indian farmers, increasing...
View Details
- November 2006 (Revised March 2008)
- Case
The Harvard Stem Cell Institute
Describes a set of issues confronting the leaders of the Harvard Stem Cell Institute, an innovative cross-university effort to accelerate scientific discovery and translation in the domain of stem cells. Covers a wide range of topics, including understanding how...
View Details
Keywords:
Talent and Talent Management;
Higher Education;
Entrepreneurship;
Collaborative Innovation and Invention;
Intellectual Property;
Research and Development;
Genetics;
Biotechnology Industry;
Health Industry;
Massachusetts
Sahlman, William A. "The Harvard Stem Cell Institute." Harvard Business School Case 807-096, November 2006. (Revised March 2008.)
- 21 Mar 2022
- Blog Post
The Impact of Career Coaching | When Mission Meets Passion
patients. My business has a deeply personal aspect for me: I have a progressive, genetic hearing loss. In addition to wearing powerful hearing aids (I was fitted with my first aid at age 12), I lip-read and use captioning in order to...
View Details
- 06 Aug 2014
- What Do You Think?
What Is Warren Bennis’s Legacy?
as the father of leadership." In an extended remembrance that Bill sent to me, he went on to say that "It was Warren who first said leadership is not a set of genetic characteristics, but rather the result of the lifelong...
View Details